Stockscreener 앱 받기
195.39
1.68%
-3.08
Abbvie Inc 주식(ABBV)의 최신 뉴스
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for InvestorsContact The Gross Law Firm - marketscreener.com
Viral Conjunctivitis Drugs Market Overall Study Report - openPR.com
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? - Yahoo Finance
Invest in These ETFs to Prepare Your Portfolio for a Recession - The Motley Fool
Allergan Aesthetics Boosts Women Entrepreneurs with BOTOX Cosmetic Initiative (ABBV) - GuruFocus
Fund Update: SATURNA CAPITAL CORP added 40,521 shares of ABBVIE ($ABBV) to their portfolio - Nasdaq
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Conta - GuruFocus
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your RightsABBV - marketscreener.com
BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project" - AbbVie News Center
AbbVie shares snap seven-session gaining streak - MSN
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV)June 3, 2025 Deadline to Join – Contact The Gross Law Firm - TradingView
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV - marketscreener.com
PTAB Axes AbbVie Unit's Cancer Drug Patent As Invalid - Law360
Androgen Drugs Market Detailed in New Research Report By 2032 | AbbVie Inc.,Endo International plc - openPR.com
FDA approves AbbVie’s upadacitinib for giant cell arteritis - Yahoo
AbbVie secures FDA approval for Rinvoq to treat giant cell arteritis - World Pharmaceutical Frontiers
In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis - insights.citeline.com
AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis - Benzinga
Why AbbVie Stock Topped the Market Today - MSN
AbbVie (NYSE:ABBV) Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis - Yahoo Finance
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - Benzinga
Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next? - Benzinga
AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News
AbbVie Says Rinvoq Medication Gets FDA Approval to Treat Giant Cell Arteritis - marketscreener.com
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
AbbVie (ABBV) Target Price Increased Following Strong Quarterly Results | ABBV Stock News - GuruFocus
FDA Approval for AbbVie's Rinvoq (ABBV) in Treating Giant Cell A - GuruFocus
RINVOQ® Receives U.S. FDA Approval for Giant Cell Arteritis - Investing News Network
Guggenheim Adjusts AbbVie Price Target to $216 From $214, Maintains Buy Rating - marketscreener.com
Morgan Stanley Boosts AbbVie (ABBV) Price Target to $250 | ABBV Stock News - GuruFocus
Why AbbVie Stock Trounced the Market Today - MSN
AbbVie (ABBV) Stock Rises on Positive Analyst Notes - GuruFocus
Maybe In May: US FDA Calls Coming On Moderna Next-Gen COVID-19 Vaccine, AbbVie’s Big ADC Bet - insights.citeline.com
S&P 500 Gains and Losses Today: AbbVie Stock Advances After Beat-and-Raise Earnings Report - Investopedia
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst - Benzinga
AbbVie (ABBV) Target Price Raised as Confidence Grows in Long-Te - GuruFocus
AbbVie (ABBV) Sees Price Target Boost from BofA | ABBV Stock New - GuruFocus
AbbVie Stock Rises. Earnings Beat, Guidance Raised But Trump Tariffs May Bite. - Barron's
HSBC Adjusts Price Target for AbbVie (ABBV) Amid Potential Tarif - GuruFocus
AbbVie Lifts Profit Guidance as Newer Drugs Drive Sales Beat - MSN
HSBC Adjusts Price Target on AbbVie to $205 From $230, Maintains Buy Rating - marketscreener.com
AbbVie makes its tariffs-driven investment play - Pharmaphorum
AbbVie lifts profit forecast on strong sales of newer immunology drugs - MSN
Should Investors Be Worried About Dividend King AbbVie? - Nasdaq
Why AbbVie’s Stock Is A Strong Buy After Q1 2025 Results (NYSE:ABBV) - Seeking Alpha
AbbVie Stock (ABBV) Up 8% on the Week as Company Soars Past Q1 Expectations - markets.businessinsider.com
AbbVie Inc. (ABBV): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential - Insider Monkey
AbbVie First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
AbbVie (ABBV) Stock: Q1 Earnings Beat and EPS Outlook Raised - CoinCentral
AbbVie (ABBV) Boosts Earnings Forecast as Q1 Results Beat Expectations - GuruFocus
AbbVie Inc. (NYSE:ABBV) Q1 2025 Earnings Call Transcript - MSN
AbbVie (ABBV) Boosts Revenue Forecast Amid Strong Q1 Results - GuruFocus
AbbVie Inc (ABBV) Q1 2025 Earnings Call Highlights: Strong Growth in Immunology and ... - Yahoo Finance
AbbVie Inc (ABBV) Q1 2025 Earnings Call Highlights: Strong Growt - GuruFocus
AbbVie Reports Strong Q1 2025 Financial Results - TipRanks
AbbVie: Q1 Earnings Snapshot - New Haven Register
How Much Would It Take To Earn $100 A Month From AbbVie Stock - Yahoo Finance
0.64%
0.21%
자본화:
|
볼륨(24시간):